sorafenib has been researched along with Leucocythaemia in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (25.00) | 29.6817 |
| 2010's | 7 (58.33) | 24.3611 |
| 2020's | 2 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Garcia-Manero, G; Hu, Y; Huang, K; Huang, P; Li, Y; Liu, Q; Lu, W; Luo, B; Tian, T; Wen, S; Yin, F; Zhang, S | 1 |
| Chen, X; Dai, M; Fan, Z; Huang, F; Huang, J; Liang, X; Liu, H; Liu, Q; Nie, D; Shi, P; Sun, J; Sun, Q; Wang, Z; Xu, J; Xu, N; Xuan, L; Yu, G; Zhang, X; Zhang, Y | 1 |
| Garcia-Manero, G; Hu, Y; Huang, P; Jiang, W; Lu, W; Tian, J; Wen, S; You, X; Yu, T; Zhang, H | 1 |
| Beraza, N; Musso, O | 1 |
| Gerber, JM; Grunwald, MR; Induru, R; McDonnell, MH | 1 |
| Brüning, A; Friese, K; Gingelmaier, A; Rahmeh, M | 1 |
| Baker, SD; Campana, D; Christensen, R; Coustan-Smith, E; Furmanski, BD; Heym, KM; Inaba, H; Li, L; Mascara, GP; Onciu, M; Pounds, SB; Pui, CH; Ribeiro, RC; Rubnitz, JE; Shurtleff, SA | 1 |
| Fiedler, W; Wellbrock, J | 1 |
| Adamson, PC; Balis, FM; Baruchel, S; Blaney, SM; Burke, M; Fox, E; Glade Bender, J; Ingle, AM; Kim, A; Stempak, D; Weigel, B; Widemann, BC | 1 |
| Bauer, C; Davis, EM; Dent, P; Grant, S; Rahmani, M | 1 |
| Almenara, JA; Coe, S; Grant, S; Rosato, RR | 1 |
| El-Deiry, WS; Kim, SH; Ricci, MS | 1 |
3 review(s) available for sorafenib and Leucocythaemia
| Article | Year |
|---|---|
Cutaneous manifestations in leukemia patients.
Topics: Adenine Nucleotides; Antineoplastic Agents; Arabinonucleosides; Clofarabine; Cytarabine; Dermatomycoses; Etoposide; Humans; Leukemia; Mastocytosis; Niacinamide; Paraneoplastic Syndromes; Phenylurea Compounds; Skin Diseases, Bacterial; Skin Neoplasms; Sorafenib | 2016 |
Clinical experience with antiangiogenic therapy in leukemia.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Clinical Trials as Topic; Humans; Indoles; Lenalidomide; Leukemia; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Quinazolines; Sorafenib; Staurosporine; Sunitinib; Thalidomide; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A | 2011 |
Mcl-1: a gateway to TRAIL sensitization.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Down-Regulation; Drug Resistance, Neoplasm; Drug Synergism; Humans; Leukemia; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Proteins; Neoplasms; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-bcl-2; Pyridines; Sorafenib; TNF-Related Apoptosis-Inducing Ligand | 2008 |
3 trial(s) available for sorafenib and Leucocythaemia
| Article | Year |
|---|---|
A phase 2 study of sorafenib combined with conventional therapies in refractory central nervous system leukemia.
Topics: Central Nervous System; Central Nervous System Neoplasms; Graft vs Host Disease; Humans; Leukemia; Recurrence; Retrospective Studies; Sorafenib | 2022 |
Phase I pharmacokinetic and pharmacodynamic study of the multikinase inhibitor sorafenib in combination with clofarabine and cytarabine in pediatric relapsed/refractory leukemia.
Topics: Adenine Nucleotides; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Benzenesulfonates; Child; Clofarabine; Cytarabine; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Leukemia; Leukemia, Myeloid, Acute; Male; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Recurrence; Sorafenib | 2011 |
A phase I trial and pharmacokinetic study of sorafenib in children with refractory solid tumors or leukemias: a Children's Oncology Group Phase I Consortium report.
Topics: Adolescent; Antineoplastic Agents; Child; Child, Preschool; Female; Humans; Leukemia; Male; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Treatment Outcome; Young Adult | 2012 |
6 other study(ies) available for sorafenib and Leucocythaemia
| Article | Year |
|---|---|
Identification of the Benzoimidazole Compound as a Selective FLT3 Inhibitor by Cell-Based High-Throughput Screening of a Diversity Library.
Topics: Animals; Antineoplastic Agents; Benzimidazoles; Cell Line; Cell Line, Tumor; fms-Like Tyrosine Kinase 3; High-Throughput Screening Assays; Humans; Leukemia; Male; Mice; Mice, Inbred BALB C; Protein Kinase Inhibitors; Rats; Rats, Sprague-Dawley; Small Molecule Libraries; Solubility; Xenograft Model Antitumor Assays | 2022 |
Metabolic reprogramming and redox adaptation in sorafenib-resistant leukemia cells: detected by untargeted metabolomics and stable isotope tracing analysis.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carbon Isotopes; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase 3; Glucose; Glutathione; Humans; Leukemia; Mass Spectrometry; Metabolomics; Mice; NADP; Oxidation-Reduction; Pentose Phosphate Pathway; Protein Kinase Inhibitors; Sorafenib | 2019 |
Hepatocellular carcinomas: evolution to sorafenib resistance through hepatic leukaemia factor.
Topics: Carcinoma, Hepatocellular; Humans; Leukemia; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib | 2019 |
The mitochondria-independent cytotoxic effect of nelfinavir on leukemia cells can be enhanced by sorafenib-mediated mcl-1 downregulation and mitochondrial membrane destabilization.
Topics: Apoptosis; Benzenesulfonates; Bone Marrow Cells; Caspase 8; CDC2 Protein Kinase; Cell Cycle; Cell Line, Tumor; Cyclin B; Dose-Response Relationship, Drug; Down-Regulation; Drug Screening Assays, Antitumor; Enzyme Activation; Gene Expression Regulation, Leukemic; Humans; Leukemia; Membrane Potential, Mitochondrial; Mitochondria; Mitochondrial Membranes; Myeloid Cell Leukemia Sequence 1 Protein; Nelfinavir; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-bcl-2; Pyridines; Sorafenib; Up-Regulation | 2010 |
Apoptosis induced by the kinase inhibitor BAY 43-9006 in human leukemia cells involves down-regulation of Mcl-1 through inhibition of translation.
Topics: Antineoplastic Agents; Apoptosis; Benzenesulfonates; Caspase 3; Caspase 7; Caspase 9; Caspases; Cell Line, Tumor; Chromatography; Dose-Response Relationship, Drug; Down-Regulation; Enzyme Inhibitors; Genes, Reporter; Humans; Immunoblotting; Immunoprecipitation; Jurkat Cells; K562 Cells; Leukemia; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Proteins; Niacinamide; Phenylurea Compounds; Phosphorylation; Promoter Regions, Genetic; Protein Biosynthesis; Proto-Oncogene Proteins c-bcl-2; Pyridines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sorafenib; Subcellular Fractions; Time Factors; Transcription, Genetic; Transfection; U937 Cells; Ubiquitin | 2005 |
The multikinase inhibitor sorafenib potentiates TRAIL lethality in human leukemia cells in association with Mcl-1 and cFLIPL down-regulation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-2 Homologous Antagonist-Killer Protein; bcl-2-Associated X Protein; Benzenesulfonates; CASP8 and FADD-Like Apoptosis Regulating Protein; Caspase 8; Death Domain Receptor Signaling Adaptor Proteins; Down-Regulation; Drug Synergism; Humans; Leukemia; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Proteins; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-bcl-2; Pyridines; Receptors, TNF-Related Apoptosis-Inducing Ligand; Receptors, Tumor Necrosis Factor; Sorafenib; TNF-Related Apoptosis-Inducing Ligand; U937 Cells | 2007 |